0001104659-24-073391.txt : 20240620 0001104659-24-073391.hdr.sgml : 20240620 20240620161035 ACCESSION NUMBER: 0001104659-24-073391 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240620 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Other Events FILED AS OF DATE: 20240620 DATE AS OF CHANGE: 20240620 FILER: COMPANY DATA: COMPANY CONFORMED NAME: IRONWOOD PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001446847 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 043404176 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34620 FILM NUMBER: 241056311 BUSINESS ADDRESS: STREET 1: 100 SUMMER STREET, SUITE 2300 CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 617-621-7722 MAIL ADDRESS: STREET 1: 100 SUMMER STREET, SUITE 2300 CITY: BOSTON STATE: MA ZIP: 02110 8-K 1 tm2417654d1_8k.htm FORM 8-K
false 0001446847 0001446847 2024-06-20 2024-06-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

Current Report Pursuant to 

Section 13 or 15(d) of the 

Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported):

June 20, 2024

 

IRONWOOD PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-34620   04-3404176
(State or other jurisdiction   (Commission File Number)   (I.R.S. Employer
of incorporation)     Identification Number)

 

100 Summer Street, Suite 2300        
Boston, Massachusetts       02110
(Address of principal
executive offices)		       (Zip code)

 

(617) 621-7722 

(Registrant’s telephone number,

including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act: 

Title of each class Trading Symbol(s) Name of each exchange on which
registered
Class A common stock, $0.001 par value IRWD Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On June 18, 2024, the Board of Directors of Ironwood Pharmaceuticals, Inc. (the “Company”) appointed Sravan K. Emany, age 46, the Company’s Senior Vice President, Chief Financial Officer, to the position of Senior Vice President, Chief Operating Officer and Chief Financial Officer, effective immediately. Mr. Emany has served as the Company’s Senior Vice President, Chief Financial Officer since December 6, 2021. For more information regarding Mr. Emany’s background, please see Mr. Emany’s biography set forth in the Company’s Definitive Proxy Statement on Schedule 14A for its 2024 Annual Meeting of Stockholders, filed with the Securities and Exchange Commission on April 25, 2024.

 

There is no arrangement or understanding between Mr. Emany and any other person pursuant to which Mr. Emany was appointed as the Company’s Chief Operating Officer and Chief Financial Officer. There is no family relationship between Mr. Emany and any director, executive officer, or person nominated or chosen by the Company to become a director or executive officer of the Company. Mr. Emany is not and has not been a participant in any transaction involving the Company, and is not and has not been a participant in any proposed transaction with the Company, required to be disclosed pursuant to Item 404(a) of Regulation S-K under the Securities Exchange Act of 1934, as amended.

 

Item 8.01. Other Events.

 

On June 17, 2024, the Company repaid in full its 0.75% Convertible Senior Notes due 2024 (the “2024 Convertible Notes”) upon maturity. Prior to their maturity and repayment, there was a $200 million aggregate principal amount of 2024 Convertible Notes outstanding. The 2024 Convertible Notes were repaid using $50 million of cash on hand and $150 million withdrawn from the Company’s $500 million secured revolving facility that it entered into in May 2023 (the “Revolving Credit Facility”). Following the repayment of the 2024 Convertible Notes, the outstanding principal balance of the Revolving Credit Facility was $425 million. The Company currently expects to have approximately $100 million of cash and cash equivalents as of June 30, 2024. This estimate is preliminary and is subject to change pending the actual results of, and completion of, the Company’s condensed consolidated financial statements for the quarter ending June 30, 2024.

 

This Current Report on Form 8-K contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about the Company’s expectations regarding its cash and cash equivalents balance as of June 30, 2024. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include that the Company may incur unanticipated expenses or generate lower than anticipated cash from operations, and the risks listed under the heading “Risk Factors” and elsewhere in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, and in its subsequent Securities and Exchange Commission filings. These forward-looking statements speak only as of the date of this Current Report on Form 8-K, and the Company undertakes no obligation to update these forward-looking statements.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Ironwood Pharmaceuticals, Inc.
     
Dated: June 20, 2024 By: /s/ Thomas McCourt
    Name: Thomas McCourt
    Title: Chief Executive Officer

 

 

 

 EX-101.SCH 2 irwd-20240620.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 irwd-20240620_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 4 irwd-20240620_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Cover
Jun. 20, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 20, 2024
Entity File Number 001-34620
Entity Registrant Name IRONWOOD PHARMACEUTICALS, INC.
Entity Central Index Key 0001446847
Entity Tax Identification Number 04-3404176
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 100 Summer Street
Entity Address, Address Line Two Suite 2300
Entity Address, City or Town Boston
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02110
City Area Code 617
Local Phone Number 621-7722
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Class A common stock, $0.001 par value
Trading Symbol IRWD
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://ironwoodpharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports irwd-20240620.xsd irwd-20240620_lab.xml irwd-20240620_pre.xml tm2417654d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2417654d1_8k.htm": { "nsprefix": "irwd", "nsuri": "http://ironwoodpharma.com/20240620", "dts": { "schema": { "local": [ "irwd-20240620.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "irwd-20240620_lab.xml" ] }, "presentationLink": { "local": [ "irwd-20240620_pre.xml" ] }, "inline": { "local": [ "tm2417654d1_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://ironwoodpharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-06-20", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2417654d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-20", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2417654d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0001104659-24-073391-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-073391-xbrl.zip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tm2417654d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001446847 2024-06-20 2024-06-20 iso4217:USD shares iso4217:USD shares false 0001446847 8-K 2024-06-20 IRONWOOD PHARMACEUTICALS, INC. DE 001-34620 04-3404176 100 Summer Street Suite 2300 Boston MA 02110 617 621-7722 false false false false Class A common stock, $0.001 par value IRWD NASDAQ false